Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol
    April 2024
  1. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    >> Share

  2. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    >> Share

    March 2024
  3. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    >> Share

  4. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    >> Share

    February 2024
  5. WU C, Li J, Jia H, Zhao J, et al
    Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
    J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
    >> Share

  6. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    >> Share

    January 2024
  7. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    >> Share

  8. HANAI T, Nishimura K, Unome S, Miwa T, et al
    A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
    J Gastroenterol. 2024;59:45-55.
    >> Share

    December 2023
  9. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    >> Share

  10. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    >> Share

  11. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    >> Share

    November 2023
  12. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    >> Share

    October 2023
  13. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    >> Share

  14. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    >> Share

  15. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    >> Share

    September 2023
  16. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    >> Share

  17. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    >> Share

  18. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    >> Share

  19. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    >> Share

    August 2023
  20. YANG L, Tian S, Zheng X, Zhang M, et al
    N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.
    J Gastroenterol. 2023;58:718-733.
    >> Share

  21. TADA F, Hiraoka A, Tada T, Hirooka M, et al
    Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
    J Gastroenterol. 2023 Aug 1. doi: 10.1007/s00535-023-02026.
    >> Share

    July 2023
  22. XIE C, Ye X, Zeng L, Zeng X, et al
    Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    J Gastroenterol. 2023 Jul 27. doi: 10.1007/s00535-023-02011.
    >> Share

  23. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    >> Share

  24. LI L, Wu PS, Liang XM, Chen K, et al
    Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.
    J Gastroenterol. 2023 Jul 14. doi: 10.1007/s00535-023-02018.
    >> Share

  25. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    >> Share

  26. CHEN G, Zhu W, Liu Y, Zhang L, et al
    The clonal heterogeneity of colon cancer with liver metastases.
    J Gastroenterol. 2023;58:642-655.
    >> Share

    June 2023
  27. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    >> Share

    May 2023
  28. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    >> Share

  29. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    >> Share

  30. YE MP, Lu WL, Rao QF, Li MJ, et al
    Mitochondrial stress induces hepatic stellate cell activation in response to the ATF4/TRIB3 pathway stimulation.
    J Gastroenterol. 2023 May 7. doi: 10.1007/s00535-023-01996.
    >> Share

    April 2023
  31. NAKAI M, Morikawa K, Sasaki T, Kohya R, et al
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 2023 Apr 27. doi: 10.1007/s00535-023-01993.
    >> Share

    March 2023
  32. YAMAUCHI R, Ito T, Yoshio S, Yamamoto T, et al
    Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2023 Mar 30. doi: 10.1007/s00535-023-01985.
    >> Share

  33. GAO TM, Zhou J, Xiang XX, Jin SJ, et al
    plenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
    J Gastroenterol. 2023 Mar 21. doi: 10.1007/s00535-023-01982.
    >> Share

  34. CHANG X, Li Y, Sun C, Li X, et al
    High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2023 Mar 16. doi: 10.1007/s00535-023-01970.
    >> Share

  35. FU Y, Peng W, Zhang W, Yang Z, et al
    Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01976.
    >> Share

  36. MA L, Liu Y, Yan Z, Zhang W, et al
    Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01977.
    >> Share

    February 2023
  37. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
    Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
    >> Share

  38. KAMADA Y, Nakamura T, Isobe S, Hosono K, et al
    SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
    J Gastroenterol. 2023;58:79-97.
    >> Share

  39. TSUGE M, Kawaoka T, Oka S
    Factors for the recurrence of hepatocellular carcinoma after hepatic resection.
    J Gastroenterol. 2023 Feb 1. doi: 10.1007/s00535-023-01962.
    >> Share

    January 2023
  40. ZHANG X, Durham KM, Garza AA, Murali AR, et al
    Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension.
    J Gastroenterol. 2023 Jan 24. doi: 10.1007/s00535-023-01957.
    >> Share

  41. NAKAYAMA H, Okamura Y, Higaki T, Moriguchi M, et al
    Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis.
    J Gastroenterol. 2023 Jan 2. doi: 10.1007/s00535-022-01946.
    >> Share

  42. SAKAI N, Kamimura K, Miyamoto H, Ko M, et al
    Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17beta-hydroxysteroid dehydrogenase 13 expression.
    J Gastroenterol. 2023;58:53-68.
    >> Share

    December 2022
  43. ISHIKAWA T, Egusa M, Fujioka T, Nishiyama N, et al
    A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
    J Gastroenterol. 2022 Dec 30. doi: 10.1007/s00535-022-01947.
    >> Share

  44. SATAKE T, Morizane C, Rikitake R, Higashi T, et al
    Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry.
    J Gastroenterol. 2022 Dec 23. doi: 10.1007/s00535-022-01944.
    >> Share

    November 2022
  45. LIN YC, Lin HF, Wu CC, Chen CL, et al
    Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity.
    J Gastroenterol. 2022;57:913-925.
    >> Share

    September 2022
  46. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    J Gastroenterol. 2022 Sep 29. pii: 10.1007/s00535-022-01925.
    >> Share

  47. SATAKE T, Morizane C, Rikitake R, Higashi T, et al
    The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry.
    J Gastroenterol. 2022 Sep 26. pii: 10.1007/s00535-022-01920.
    >> Share

    August 2022
  48. ZHOU Q, Wang X, Li R, Wang C, et al
    Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Aug 3. pii: 10.1007/s00535-022-01910.
    >> Share

    July 2022
  49. KODAMA K, Kawaoka T, Kosaka M, Johira Y, et al
    Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
    J Gastroenterol. 2022 Jul 18. pii: 10.1007/s00535-022-01887.
    >> Share

  50. ZHOU Q, Wang X, Li R, Wang C, et al
    Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Jul 11. pii: 10.1007/s00535-022-01895.
    >> Share

  51. LIU T, Liao S, Mo J, Bai X, et al
    LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.
    J Gastroenterol. 2022 Jul 8. pii: 10.1007/s00535-022-01901.
    >> Share

  52. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    >> Share

    June 2022
  53. KARIYAMA K, Hiraoka A, Kumada T, Yasuda S, et al
    Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    J Gastroenterol. 2022 Jun 28. pii: 10.1007/s00535-022-01883.
    >> Share

    May 2022
  54. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    >> Share

    April 2022
  55. NISHIDA N, Yamakawa M, Shiina T, Mekada Y, et al
    Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.
    J Gastroenterol. 2022;57:309-321.
    >> Share

  56. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    >> Share

    March 2022
  57. SUZUKI Y, Mori T, Momose H, Matsuki R, et al
    Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.
    J Gastroenterol. 2022 Mar 31. pii: 10.1007/s00535-022-01868.
    >> Share

  58. LIN W, Lin J, Li J, Lin Y, et al
    Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
    J Gastroenterol. 2022 Mar 4. pii: 10.1007/s00535-022-01866.
    >> Share

    February 2022
  59. WANG XH, Hu ZL, Fu YZ, Hou JY, et al
    Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    J Gastroenterol. 2022 Feb 13. pii: 10.1007/s00535-022-01855.
    >> Share

    January 2022
  60. SAKAMORI R, Yamada R, Tahata Y, Kodama T, et al
    The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    J Gastroenterol. 2022 Jan 22. pii: 10.1007/s00535-021-01842.
    >> Share

  61. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    >> Share

  62. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    >> Share

    December 2021
  63. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    >> Share

  64. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    >> Share

  65. KAMADA Y, Takahashi H, Shimizu M, Kawaguchi T, et al
    Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
    J Gastroenterol. 2021;56:1045-1061.
    >> Share

    November 2021
  66. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    >> Share

  67. YONEDA M, Yamamoto T, Honda Y, Imajo K, et al
    Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    J Gastroenterol. 2021;56:1022-1032.
    >> Share

    September 2021
  68. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    >> Share

  69. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
    Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
    >> Share

    July 2021
  70. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.
    >> Share

  71. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    >> Share

  72. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.
    >> Share

    May 2021
  73. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    >> Share

    January 2021
  74. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.
    >> Share

  75. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    >> Share

  76. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    >> Share

    August 2020
  77. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    >> Share

    December 2019
  78. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016